KBI Biopharma, Inc. Announces Collaboration with Infinimmune Inc. to Support Antibody Manufacturing
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), and Infinimmune, Inc., a biotechnology company pioneering human-first antibody discovery and design, announced a collaboration to advance manufacturing of Infinimmune’s lead human monoclonal antibody (“IFX-101”) program.
The first antibody in Infinimmune’s therapeutic drug development pipeline, IFX-101, targets atopic dermatitis and is designed to deliver superior efficacy with extended dosing intervals for improved patient quality of life. By sourcing antibodies directly from the human immune system, Infinimmune taps into a naturally optimized, safe, and effective therapeutic reservoir, rather than engineering from scratch. Infinimmune’s GLIMPSE™ platform – a protein language model trained solely on native human antibody sequences – learns from millions of successful immune responses to engineer superior antibodies that harness evolution-proven strategies with enhanced biologic properties. This combination creates a potent platform that’s uniquely differentiated in the biologics field.
“We are pleased to partner with KBI Biopharma to advance our lead antibody program,” said Wyatt McDonnell, Ph.D., CEO and Co-Founder, Infinimmune. “By combining our Anthrobody® and GLIMPSE™ platforms together with KBI’s development and manufacturing expertise, we’re positioned to rapidly advance toward clinical trials. Our human-first approach enables us to deliver what patients really need – more effective treatments with greater convenience. This collaboration is an important step in our mission to bring transformative, human-first antibodies to patients in need."
“KBI is proud to support Infinimmune in its effort to transform biologics and deliver safer, more effective antibody therapeutics,” said Katie Edgar, Chief Business Officer of KBI Biopharma. “Our strategic partnership will be highly synergistic in biologics development, by combining Infinimmune’s cutting-edge antibody discovery with KBI’s deep expertise in development and manufacturing capabilities.”
The IFX-101 program is progressing at KBI’s Cell Line Development Center of Excellence in Geneva, Switzerland, using KBI’s advanced monoclonal antibody development and manufacturing platform, SUREmAb™, powered by Selexis.
About Infinimmune
Infinimmune is a biotechnology company pioneering a novel approach to antibody drug discovery and development. Founded by a world-class, multidisciplinary team of scientists and technologists, Infinimmune is reinventing antibody discovery with an end-to-end platform to deliver antibody drugs derived directly from the human immune system. These truly human antibodies are designed to drug new and existing targets with improved safety and efficacy. Infinimmune is building its own pipeline of drug candidates and partnering with pharmaceutical companies to advance their antibody programs, fill their pipelines, and reach new patients and new indications. To learn more, visit infinimmune.com and follow us on LinkedIn and @infinimmune.
About KBI Biopharma, Inc.
KBI Biopharma, Inc., a JSR Life Sciences company, together with its affiliates, is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. As a global leader in mammalian cell line development, with best-in-class modular technology and highly specialized solutions, KBI enables the life sciences industry to rapidly discover, develop, and commercialize innovative medicines and vaccines. With each of its 500+ customer partners, KBI works closely to personalize and rapidly accelerate drug development programs.
Global partners are utilizing KBI’s technologies to advance more than 170 drug candidates in preclinical and clinical development and the manufacture of ten commercial products. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian and microbial programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates to the market. KBI serves its global customers with six locations in Europe and the USA. More information is available at www.kbibiopharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250908013845/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
De’Longhi Launches the Perfetto 3.0 Global Campaign Starring Brad Pitt to Solidify Its Worldwide Coffee Leadership8.9.2025 19:43:00 CEST | Press release
Premiered at the Venice Film Festival, the new campaign captures the emotions and experience of the Perfetto coffee ritual De’Longhi has launched its third global campaign centered on the world of coffee on the occasion of the 82nd Venice Film Festival, where the brand is a supporter and present with special activations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250908690655/en/ Brad drinking coffee The new campaign reflects De’Longhi’s continued evolution into alifestyle brand rooted in Italian design and innovation. This 3rd chapter builds upon a proven track record from recent years, which has supported the Group in growing the business and solidifying its market leadership. This campaign is set to be the Group's most extensive to date, with significant consumer reach across all traditional, digital, and social media channels, engaging and targeting the broadest possible audience among coffee lovers and prospective c
Second Front Systems to Launch Game Warden® Platform on AWS European Sovereign Cloud8.9.2025 18:31:00 CEST | Press release
Availability on AWS European Sovereign Cloud will enable accelerated ISV compliance and deployment while meeting stringent data sovereignty requirements. Second Front Systems (2F), a Technology Partner in the Amazon Web Services (AWS) Partner Network (APN), today announced that its 2F Game Warden® platform will be available on AWS European Sovereign Cloud. The announcement builds on Second Front's deep technical expertise and proven customer success in delivering security solutions on AWS. Organizations across Europe face complex regulatory requirements, including Germany's C5, and the EU's Digital Operational Resilience Act (DORA) and NIS2 Directive. The availability of 2F Game Warden on AWS European Sovereign Cloud provides a pre-validated solution that helps customers meet these stringent compliance requirements while maintaining data residency within EU borders. “Digital sovereignty isn’t just about compliance—it’s about building trust and resilience,” said Tyler Sweatt, CEO of Sec
Experian Ranked 6th in 2025 IDC FinTech Rankings: Top 1008.9.2025 18:15:00 CEST | Press release
Places in the top-10 global technology providers for the fourth consecutive year Experian today announced that it was ranked 6th in the 2025 IDC FinTech Rankings: Top 100, rising one spot from last year’s rankings and placing in the top-10 global technology providers for the fourth consecutive year. The FinTech Rankings feature enterprise companies from around the world that serve multiple industries and generate significant revenues from the financial services and FinTech industries. “Experian helps financial services organizations tackle their toughest business challenges by delivering continuous innovation in AI decisioning, advanced analytics, and fraud prevention,” said Alex Lintner, CEO of Experian Technology & Software. “As one of the world’s largest FinTech companies, this recognition underscores how we empower customers globally to accelerate operations, expand financial inclusion, reduce risk with transformative AI, and ultimately drive stronger business results.” A prime exa
Balsam Hill Proudly Announces Its Commitment to a More Sustainable Christmas Tree8.9.2025 18:00:00 CEST | Press release
Balsam Hill®, the global leader in high-quality, true-to-nature, reusable, artificial Christmas trees and holiday décor, proudly announces an innovation in how its heirloom-quality Christmas trees are now being made using more sustainable materials. Since 2006, Balsam Hill has been committed to reusability, quality, realism, and innovation in the Christmas trees its millions of customers have come to love. In that spirit, Balsam Hill is proud to be the first retailer in the world to offer Christmas trees with True Needle® tips made with plant-based polyethylene, derived from sugarcane, not fossil fuels. And just as exciting, as of the holiday 2025 season production line, all the brand’s other True Needle trees will now incorporate 30% post-consumer GRS-certified recycled polyethylene made from tear-away water bottle caps. Both changes were made without sacrificing the quality controls and safety considerations required for each Balsam Hill tree, including the company’s three-year warra
Xsolla and Global Game Jam Announce a New Webinar to Help Indie Developers Grow Player Bases and Generate First Sales for Their Games8.9.2025 18:00:00 CEST | Press release
Practical Strategies For Attracting Players And Monetizing Games Will Be Shared In A Live Panel Featuring Xsolla Leaders, Game Developers, And Industry Experts Xsolla, a leading global video game commerce company, announces a new collaboration with Global Game Jam (GGJ) to host a live webinar for indie developers titled “From Zero to 1K: Growing Your Player Base and Making Your First $$.” The session will take place on Tuesday, September 9, 2025, at 10:00 AM PT, offering actionable strategies to help developers attract their first audience and begin generating sustainable revenue. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250908673871/en/ (Graphic: Xsolla) Bringing together game industry leaders and experienced developers, the event will provide beginner-friendly insights on how to make a game appealing to players while establishing effective monetization tactics. Attendees will learn how to avoid common early mistakes
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom